JP7141408B2 - 前立腺癌の併用療法 - Google Patents

前立腺癌の併用療法 Download PDF

Info

Publication number
JP7141408B2
JP7141408B2 JP2019555852A JP2019555852A JP7141408B2 JP 7141408 B2 JP7141408 B2 JP 7141408B2 JP 2019555852 A JP2019555852 A JP 2019555852A JP 2019555852 A JP2019555852 A JP 2019555852A JP 7141408 B2 JP7141408 B2 JP 7141408B2
Authority
JP
Japan
Prior art keywords
niraparib
patient
pharmaceutical composition
prednisone
abiraterone acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019555852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516646A (ja
JP2020516646A5 (enExample
Inventor
ケー． ユ，マーガレット
アン スナイダー，リンダ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7141408(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2020516646A publication Critical patent/JP2020516646A/ja
Publication of JP2020516646A5 publication Critical patent/JP2020516646A5/ja
Priority to JP2022117192A priority Critical patent/JP7407880B2/ja
Application granted granted Critical
Publication of JP7141408B2 publication Critical patent/JP7141408B2/ja
Priority to JP2023196574A priority patent/JP2024023344A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2019555852A 2017-04-13 2018-04-09 前立腺癌の併用療法 Active JP7141408B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022117192A JP7407880B2 (ja) 2017-04-13 2022-07-22 前立腺癌の併用療法
JP2023196574A JP2024023344A (ja) 2017-04-13 2023-11-20 前立腺癌の併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
US62/485,164 2017-04-13
PCT/US2018/026661 WO2018191141A1 (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022117192A Division JP7407880B2 (ja) 2017-04-13 2022-07-22 前立腺癌の併用療法

Publications (3)

Publication Number Publication Date
JP2020516646A JP2020516646A (ja) 2020-06-11
JP2020516646A5 JP2020516646A5 (enExample) 2021-07-26
JP7141408B2 true JP7141408B2 (ja) 2022-09-22

Family

ID=62067858

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019555852A Active JP7141408B2 (ja) 2017-04-13 2018-04-09 前立腺癌の併用療法
JP2022117192A Active JP7407880B2 (ja) 2017-04-13 2022-07-22 前立腺癌の併用療法
JP2023196574A Pending JP2024023344A (ja) 2017-04-13 2023-11-20 前立腺癌の併用療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022117192A Active JP7407880B2 (ja) 2017-04-13 2022-07-22 前立腺癌の併用療法
JP2023196574A Pending JP2024023344A (ja) 2017-04-13 2023-11-20 前立腺癌の併用療法

Country Status (33)

Country Link
US (4) US20180296574A1 (enExample)
EP (3) EP4176879A1 (enExample)
JP (3) JP7141408B2 (enExample)
KR (2) KR20190134718A (enExample)
CN (2) CN119235874A (enExample)
AU (2) AU2018251594A1 (enExample)
CA (1) CA3059562A1 (enExample)
CL (1) CL2019002871A1 (enExample)
CO (1) CO2019011591A2 (enExample)
CR (1) CR20190467A (enExample)
DK (1) DK3609497T3 (enExample)
DO (1) DOP2019000264A (enExample)
EA (1) EA201992430A1 (enExample)
ES (1) ES2931052T3 (enExample)
HR (1) HRP20221327T1 (enExample)
HU (1) HUE060460T2 (enExample)
IL (2) IL269879B2 (enExample)
JO (2) JOP20190244B1 (enExample)
LT (1) LT3609497T (enExample)
MA (1) MA48728B1 (enExample)
MD (1) MD3609497T2 (enExample)
MX (2) MX2019012296A (enExample)
MY (1) MY209010A (enExample)
NI (1) NI201900105A (enExample)
PE (1) PE20200444A1 (enExample)
PH (1) PH12019502317A1 (enExample)
PL (1) PL3609497T3 (enExample)
PT (1) PT3609497T (enExample)
RS (1) RS63832B1 (enExample)
SG (1) SG11201909552VA (enExample)
SM (1) SMT202200467T1 (enExample)
UA (1) UA129514C2 (enExample)
WO (1) WO2018191141A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119606965A (zh) 2016-07-29 2025-03-14 詹森药业有限公司 治疗前列腺癌的方法
WO2020139339A1 (en) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
AU2021269115A1 (en) * 2020-05-08 2023-01-19 Janssen Pharmaceutica Nv Treatment of prostate cancer with a combination of abiraterone acetate and niraparib
KR20230159510A (ko) * 2021-03-24 2023-11-21 화이자 인코포레이티드 Ddr 유전자 돌연변이된 전이성 거세-감수성 전립선암의 치료를 위한 탈라조파립과 항안드로겐의 조합
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
TWI828471B (zh) 2021-12-15 2024-01-01 大陸商湖南慧澤生物醫藥科技有限公司 醋酸阿比特龍的自微乳組合物和應用
CN118973555A (zh) * 2022-04-07 2024-11-15 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法
WO2025027138A1 (en) * 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501575A (ja) 2006-08-25 2010-01-21 クオウガル バイオテクノロジー，インコーポレイテッド 癌を治療するための方法及び組成物
JP2010515715A (ja) 2007-01-10 2010-05-13 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501575A (ja) 2006-08-25 2010-01-21 クオウガル バイオテクノロジー，インコーポレイテッド 癌を治療するための方法及び組成物
JP2010515715A (ja) 2007-01-10 2010-05-13 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Asian Journal of Andrology，2014年，16，pp.401-406
Asia-Pac J Clinn Oncol，2012年，8(Suppl.1)，p.33(112)
ClinicalTrials.gov, NCT01576172，2012年04月12日
ClinicalTrials.gov, NCT02924766，2016年10月05日
Drugs of the Future，2013年，38(10)，pp.679-685
Journal of Clinical Oncology，2016年，34(15 suppl.) Abstract 5010
Lancet Oncol，2012年，13，pp.1210-1217
Lancet Oncol，2015年，16，pp.152-160
The Oncologist，2014年，19，pp.1231-1240

Also Published As

Publication number Publication date
CL2019002871A1 (es) 2019-12-27
ES2931052T3 (es) 2022-12-23
SG11201909552VA (en) 2019-11-28
MY209010A (en) 2025-06-16
US20240245710A1 (en) 2024-07-25
LT3609497T (lt) 2022-12-12
DOP2019000264A (es) 2020-07-15
EA201992430A1 (ru) 2020-02-28
KR20190134718A (ko) 2019-12-04
PE20200444A1 (es) 2020-02-28
EP4176879A1 (en) 2023-05-10
JP2022141881A (ja) 2022-09-29
MA48728B1 (fr) 2022-10-31
JP2024023344A (ja) 2024-02-21
EP3609497A1 (en) 2020-02-19
WO2018191141A1 (en) 2018-10-18
CA3059562A1 (en) 2018-10-18
BR112019021466A2 (pt) 2020-05-12
PT3609497T (pt) 2023-01-23
EP3609497B1 (en) 2022-10-12
US20180296574A1 (en) 2018-10-18
IL269879A (enExample) 2019-11-28
MX2019012296A (es) 2019-11-28
IL269879B2 (en) 2025-10-01
RS63832B1 (sr) 2023-01-31
MD3609497T2 (ro) 2023-03-31
HRP20221327T1 (hr) 2023-03-17
US20240398837A1 (en) 2024-12-05
JP2020516646A (ja) 2020-06-11
AU2024202346A1 (en) 2024-05-02
NI201900105A (es) 2020-03-11
MA48728A (fr) 2020-04-08
CN119235874A (zh) 2025-01-03
CN110753545A (zh) 2020-02-04
KR20260048358A (ko) 2026-04-09
JP7407880B2 (ja) 2024-01-04
SMT202200467T1 (it) 2023-01-13
MX2023009569A (es) 2023-08-22
JOP20230159A1 (ar) 2023-07-13
AU2018251594A1 (en) 2019-10-24
JOP20190244A1 (ar) 2019-10-13
AU2024202346B2 (en) 2026-01-22
CO2019011591A2 (es) 2020-02-28
US20220175801A1 (en) 2022-06-09
JOP20190244B1 (ar) 2024-04-18
IL269879B1 (en) 2025-06-01
PL3609497T3 (pl) 2023-01-23
EP4176878A1 (en) 2023-05-10
UA129514C2 (uk) 2025-05-21
PH12019502317A1 (en) 2020-07-06
HUE060460T2 (hu) 2023-03-28
IL320452A (en) 2025-06-01
CR20190467A (es) 2020-03-09
DK3609497T3 (da) 2022-10-31

Similar Documents

Publication Publication Date Title
JP7407880B2 (ja) 前立腺癌の併用療法
Hoy Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer
JP2024510612A (ja) ソトラシブ投与レジメン
JP2022518235A (ja) 進行期固形腫瘍がんの治療用ｒｎａ
HK40092155A (en) Combination therapy for prostate cancer
EA052155B1 (ru) Комбинированная терапия рака предстательной железы
EA044835B1 (ru) Комбинированная терапия рака предстательной железы
BR122022022077B1 (pt) Combinação e composição compreendendo niraparibe, acetato de abiraterona, e prednisona, seu uso para tratar câncer de próstata e kit
BR112019021466B1 (pt) Composição compreendendo niraparibe, acetato de abiraterona, e prednisona, bem como uso dos referidos compostos
Rove et al. A renaissance in the medical treatment of advanced prostate cancer
CN118043049A (zh) 用于治疗包含kras g12c突变的癌症的索托拉西布和egfr抗体
JP2024534456A (ja) 卵巣がん及び他のがんの治療のためのグルココルチコイド受容体モジュレーターの間欠投与
CN116981462A (zh) 索托拉西布给药方案
EP4665725A2 (en) Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations
HK40102675A (zh) 索托拉西布给药方案
CN118076355A (zh) 用于治疗前列腺癌的cyp11a1抑制剂
EP4161507A1 (en) Methods of treating prostate cancer
Kollepara et al. Integrating Emerging Science into Clinical Practice: Targeting Androgen Signaling in Castration Resistant Metastatic Prostate Cancer
HK40121823A (zh) 用於治疗转移性去势抵抗性前列腺癌的他拉唑帕利和恩扎卢胺的组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210512

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220908

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220909

R150 Certificate of patent or registration of utility model

Ref document number: 7141408

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250